Abstract
Background Understanding the molecular features associated with response to neoadjuvant chemoradiotherapy is an unmet clinical need in locally advanced rectal cancer (LARC). The aim of the study was to apply a high-sensitivity proteomic approach for in-depth characterization of the LARC proteome in search of patients who might have a good response to preoperative treatment and potentially be followed by a watch-and-wait strategy, rather than having immediate surgery, maximizing the therapeutic effect and quality of life.
Methods A total of 97 LARC patients treated at the Institute for Oncology and Radiology of Serbia in the period of 2018-2019 were included in the study. Patients were treated with long-course chemoradiotherapy (CRT): Radiotherapy (RT) was delivered with a total dose of 50.4 Gy in 28 fractions; concomitant chemotherapy (5-FU, 350 mg/m2 daily) and Leucovorin (25 mg/m2 daily) was administered during the first and the fifth week of RT. Patients were evaluated in week 6-8 after treatment completion with pelvic MRI scan and rigid proctoscopy. Pathohistological response after surgery was assessed according to tumor regression grading (TRG) categories by Mandard. Twenty biopsy samples taken at diagnosis were used for proteomic analysis, 9 responders (R, TRG 1-2), and 11 non-responders (NR, TRG 3-5), to achieve the maximum range of different molecular features potentially associated with response. Formalin-fixed paraffin-embedded (FFPE) biopsies were processed, and isolated proteins were digested with trypsin. The resulting peptides were analyzed by liquid chromatography coupled to a Q Exactive HF-X mass spectrometer operated in data independent mode (DIA-MS). Data analysis was performed with DIA-NN and Perseus. Data are available via ProteomeXchange with the identifier PXD040451.
Results The use of DIA-MS allowed the identification and quantification of more than 3,000 proteins per sample in general, a significant increase when compared to the 1,000 proteins previously identified by Data Dependent Acquisition-MS (DDA-MS) in LARC FFPE samples. In total, 4,849 proteins were identified in 20 rectal cancer FFPE samples. Principal Component Analysis (PCA) indicated that responders had a significantly different proteomic profile than non-responders. Statistical analysis of the two groups resulted in the identification of 915 differentially expressed proteins (DEPs) (215 in responders and 700 in non-responders, p<0.05), and 384 with more stringent criteria (p<0.01). Results indicate that some of the leading signaling pathways that correlate with response include the metabolism of RNA, MYC targets, neutrophil degranulation, cellular transport, and response to stimuli.
Conclusions The DIA-MS approach offered unprecedented proteome coverage for FFPE samples. The differentially expressed proteins and biological processes constitute interesting findings that hold the potential for improving LARC patient management.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Horizon Europe STEPUPIORS Project (HORIZON-WIDERA-2021-ACCESS-03, European Commission, Agreement No. 101079217) and the Ministry of Education and Science of the Republic of Serbia (Agreement No. 451-03-47/2023-01/200043). This article is based upon work from COST Action CA17118, supported by COST (European Cooperation in Science and Technology); www.cost.eu. We acknowledge the support of this work by the project The Greek Research Infrastructure for Personalised Medicine (pMED-GR) (MIS 5002802) which is implemented under the Action Reinforcement of the Research and Innovation Infrastructure, funded by the Operational Programme Competitiveness, Entrepreneurship, and Innovation (NSRF 2014-2020) and co-financed by Greece and the European Union (European Regional Development Fund).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study has been approved by the Ethics Committee of the Institute for Oncology and Radiology of Serbia and all patients signed informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All non-patient sensitive data produced in the present work are contained in the manuscript. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD040451.
